Shareholders Equity: The sum of preferred and common equity items.
Promis Neurosciences (PMN) had Shareholders Equity of $9.19M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-11.58M |
|
-- |
|
-- |
|
$11.75M |
|
$-11.75M |
|
$0.17M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.75M |
|
$-11.75M |
|
1.95M |
|
1.95M |
|
$-6.00 |
|
$-6.00 |
|
| Balance Sheet Financials | |
$21.46M |
|
-- |
|
-- |
|
$21.46M |
|
$12.21M |
|
-- |
|
$0.06M |
|
$12.27M |
|
$9.19M |
|
$9.19M |
|
|
Shareholders Equity |
$9.19M |
2.15M |
|
| Cash Flow Statement Financials | |
$-18.84M |
|
-- |
|
$20.94M |
|
$13.29M |
|
$15.40M |
|
$2.11M |
|
$0.65M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-126.04% |
|
-126.04% |
|
-53.97% |
|
-126.04% |
|
$4.27 |
|
$-9.64 |
|
$-9.64 |
|